制备方法,其包括如下步骤: [0030] (1)合成和扩增编码上述嵌合抗原受体的核苷酸序列,再将所述核苷酸序列克隆 到慢病毒表达载体上; [0031] (2)利用慢病毒包装质粒和步骤(1)得到的慢病毒表达载体质粒感染 293T细胞, 包装和制备慢病毒;和 [0032] (3)利用步骤(2)得到的慢病毒感染NK-92细胞,得到NKG2D CAR-NK ...
响应可溶性MICA的人工嵌合受体修饰NK92细胞的抗肿瘤活性研究 靶向识别与响应能力的嵌合抗原受体,探讨该受体对sMICA的响应能力,为增强NK92细胞的抗肿瘤活性研究提供理论依据.方法以NK细胞主要活化受体NKG2D为CAR的构造元件,应用... 陈涵 - 《新乡医学院》 被引量: 0发表: 2020年 NKG2D CAR-NK92细胞构建及其对多发性...
NK细胞在肿瘤免疫治疗中的研究进展 NKG2DNKG2DLCAR-NK肿瘤免疫治疗是近年来有望治愈肿瘤的最有效策略之一,为肿瘤患者带来了新的希望.自然杀伤(NK)细胞作为抗肿瘤免疫的第一道防线,在控制肿瘤的起始和... 胡绍雯,朱惠芳指导 - 《中国免疫学杂志》 被引量: 0发表: 2023年 过表达CXCR4的NKG2D-CAR-NK92细胞抗胰腺...
Since Ky1.1, as well as other NK cell lines such as NK92, have a high level of constitutive Vav phosphorylation (Supplementary Fig. 5) we evaluated phospo-Vav levels in freshly isolated resting splenic C57BL/6 NK cells after a 15 min exposure to cytokines. While a significant increase in...
Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic The human-derived NK-92 cell鈥揵ased CAR-NK therapy exhibits inconsistency with overall suboptimal efficacy and rapid in vivo clearance of CAR-NK92 cells i... Z Niu,M Wang,Y Yan,......
过表达CXCR4的NKG2D-CAR-NK92细胞抗胰腺癌的研究 胰腺癌早期症状表现多样,不易被诊断,晚期易转移导致患者的生存率低,被称为癌症之王,目前均无达到理想的治疗效果.CAR-T疗法近几年在血液瘤中取得了一定成功.鉴于NK细胞... 林海珍 - 《华东师范大学》 被引量: 0发表: 2022年 ...
NK92 cells were cultured in α-MEM containing 0.2 mM inositol, 0.1 mM 2- mercaptoethanol, 0.02 mM folic acid, 100 U/mL recombinant IL-2, 12.5% horse serum, 12.5% FBS. NKL cells were cultured in RPMI in the presence of 15% FBS, 2 mM L-glutamate, 100 µg/mL penicillin, 100 ...
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have the potential to provide the potential for the implementation of allogeneic "off-the-shelf" cellular therapy against cancers. Currently, most CARs are not optimized for NK cells, so new NK-tailored CARs are needed. Here,...